bluebird bio Inc BLUE.OQ BLUE.O is expected to show a rise in quarterly revenue when it reports results on November 14 for the period ending September 30 2024
The Somerville Massachusetts-based company is expected to report a 45.6% increase in revenue to $18.049 million from $12.39 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for bluebird bio Inc is for a loss of 36 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 6 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for bluebird bio Inc is $2.50, above its last closing price of $0.41.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.50 | -0.42 | -0.42 | Met | -0.8 |
Mar. 31 2024 | -0.44 | -0.44 | -0.36 | Beat | 18.3 |
Dec. 31 2023 | -0.65 | -0.66 | -0.78 | Missed | -17.8 |
Jan. 1 0001 | -0.67 | -0.67 | -0.66 | Beat | 2.2 |
Jun. 30 2023 | -0.72 | -0.72 | -0.67 | Beat | 6.4 |
Mar. 31 2023 | -0.27 | -0.37 | 0.21 | Beat | 156.8 |
Dec. 31 2022 | -0.37 | -0.44 | -0.81 | Missed | -85.8 |
Jan. 1 0001 | -1.12 | -1.12 | -0.94 | Beat | 15.8 |
This summary was machine generated November 12 at 13:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。